

## **OBI PHARMA, INC.**

### **Notice of 2026 Annual General Shareholders' Meeting (Summary Translation)**

- I. The 2026 Annual General Shareholders' Meeting (the "Meeting") will be convened at Taipei Bioinnovation Park 1F Conference Room (1F, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City) at 9:00 a.m. on Friday, June 26, 2026. The agenda for the Meeting is as follows:
1. Reported Matters
    - (1) 2025 Business Report
    - (2) 2025 Audit and Risk Management Committee's Review Report
    - (3) Status of the Sound Operating Plan of the Company
    - (4) 2025 Status of Private Placement of Securities
  2. Acknowledged Matters
    - (1) 2025 Annual Final Accounting Ledgers and Statements
    - (2) 2025 Earnings Distribution Loss Off-setting
  3. Other Proposals
    - Lifting of non-competition restrictions for the Company's directors
  4. Extemporaneous Motions
- II. Under Article 165 of the Company Act, share transfer registration for the Company will be suspended from April 28, 2026, to June 26, 2026.
- III. Under Article 172 of the Company Act, the Company shall list the convened matters and contents on MOPS (<https://mops.twse.com.tw>).
- IV. Under Article 209 of the Company Act, the lift of non-competition restriction for the directors will be proposed provided company interests are protected.
- V. Besides the announcement published in MOPS, please find the Notice of Attendance and Proxy Statement enclosed with this Meeting Notice. Kindly check and your presence is highly solicited. If you plan to attend the Meeting in person, please affix your signature or personal seal to the Sign-in Card and deliver it for registration or submit it on the day of the Meeting. If you wish to appoint a proxy to attend the Meeting, please refer to the Proxy Statement instruction and return a folded Proxy Statement with information filled. Such Proxy Statement shall be delivered to the Company's securities agent, the Register and Transfer Agency division of Taishin Securities Co., Ltd. at least five (5) days before the Meeting so that a sign-in card can be issued to the proxy.

- VI. If any shareholder solicits proxies, the Company will publish a summary of such solicitation on the Securities and Futures Commission website (<http://free.sfi.org.tw>) before May 22, 2026. For shareholders who wish to make inquiries, please refer to the website for related information (ticker: 4174).
- VII. The period during which shareholders may cast electronic votes for the Meeting will be from May 27, 2026, to June 23, 2026. The shareholders may vote online for the Meeting by accessing the “shareholders e-services” page on the Taiwan Depository and Clearing Corporation website at <https://www.stockservices.tdcc.com.tw> and casting their votes based on the instructions on the website.
- VIII. The institution responsible for tallying and verifying the votes for the Company is the Register and Transfer Agency division of Taishin Securities Co., Ltd.
- IX. Kindly note and proceed accordingly.

Sincerely Yours  
The Board of Directors of OBI Pharma, Inc.